
Overview of methods for subgroup identification in clinical trials

Ilya Lipkovich, PhD
Eli Lilly and Company





OUTLINE


- Predictive versus prognosis effects
- Data-driven versus “guidance driven” subgroup analysis
- Taxonomy of biomarker identification methods
- Software for subgroup identification. What features to look at?
- Summary

PREDICTIVE VERSUS PROGNOSTIC BIOMARKERS

- The task of personalized medicine can be “translated” into statistical language as constructing **predictive biomarker** signature that would allow identifying patients with differential treatment response
- The schematic plots show four types of relationships between the outcome and a single biomarker


X is prognostic but not predictive

(a)




X is prognostic and predictive

(b)




X is predictive but not prognostic

(c)



X is neither prognostic nor predictive

(d)



SUBGROUP ANALYSIS GUIDELINES

- Subgroup analyses are often (rightfully) viewed as data dredging
- Many authors came up with various “checklists” of principles for Subgroup Analyses
 - NHS R&D HTA Programme (Brookes et al. 2001) provides a list of 25 recommendations
 - Rothwell (2005) proposed a guideline with 21 rules
 - Sun et al (2009) listed the existing 7 plus 4 additional criteria for assessing credibility of subgroup analysis
- EMA Guideline on the Investigation of Subgroups in Confirmatory Clinical Trials (Draft, Jan 2014)
 - Recognizes issues with current SA practices that “create disincentive to properly plan the investigation of subgroups”
- The Guidelines encourage to “exercise caution” when conducting subgroup analyses, which is hard to operationalize ...



DATA-DRIVEN VS. “GUIDELINE-DRIVEN” APPROACH

- “Guideline-driven” approach fails to encompass modern scientific approaches to statistical learning and the need for evidence-based personalized/stratified/precision medicine
- A different view: **subgroup identification**/analysis is framed as a special case of **model selection**
- This helps link subgroup identification efforts with the wealth of statistical methodology on model selection
- Pre-specified is the entire biomarker/subgroup selection strategy, not specific subgroup(s)

WHAT MAKES DATA-DRIVEN SA STRATEGIES “PRINCIPLED”?

- “Complexity control” to prevent data overfitting
 - Tuning parameters controlling the search process need to be determined often in a data-driven fashion, e.g., via cross-validation
 - E.g., penalized regression, a.k.a. shrinking, regularization
- Evaluating the type I error rate for the entire subgroup search strategy
 - E.g., using resampling under null
- Obtaining “honest” estimates of treatment effect in subgroups (i.e. treatment effect expected in identified subgroups **if applied to future studies**)
 - E.g., by using resampling methods or Bayesian model averaging/empirical Bayes
 - Uncertainty associated with the entire strategy should be accounted for




TAXONOMY OF DATA-DRIVEN SA STRATEGIES

- Global outcome modeling
- Global treatment effect modeling
- Individual treatment regimes
- Local treatment effect modeling

GLOBAL OUTCOME MODELING


- Modeling underlying outcome function $f(x, t) = E(Y|X = x, T = t)$, where Y is an outcome, X is a collection of biomarkers and $T = 0, 1$ is a treatment indicator
 - computing individual treatment differences $\hat{\delta}_i = \hat{f}(x_i, 1) - \hat{f}(x_i, 0)$, $i = 1, \dots, N$, that can be further modeled as an outcome
 - allows constructing predictive score as a function of biomarkers, a biomarker signature: $\delta(x)$
- Some recent methods
 - Virtual Twins by Foster, Taylor and Ruberg (2011) [combining Random Forest for $f(x, t)$ and CART for further modeling $\delta(x)$]
 - Penalized regression (FindIT) by Imai and Ratkovic (2013)
 - Bayesian hierarchical modeling (Jones et al, 2011 extending Dixon and Simon, 1991)
 - Bayesian trees (Henderson et al, 2017; Zhao et al, 2018)



GLOBAL TREATMENT EFFECT MODELING

- Directly modeling underlying treatment effect, $\delta(\mathbf{x})$
 - Classification and regression tree methods can be adopted by incorporating treatment variable in the splitting criterion, resulting in piecewise constant fit for $\delta(\mathbf{x})$
 - Parametric models were proposed that obviate the need for fitting in prognostic effects
- Some recent methods
 - Interaction trees, **IT** (Su et al., 2008, 2009)
 - **Gi** method (Loh et al., 2015), implemented within GUIDE suite
 - Model-based recursive partitioning (Seibold et al., 2014).
 - Modified covariate method by Tian et al. (2014)
 - **quint** method by Dusseldorp and Mechelen (2014)


$$\delta(\mathbf{x}) = f(\mathbf{x}, 1) - f(\mathbf{x}, 0)$$



MODELING INDIVIDUAL TREATMENT REGIMES

■ Estimating optimal treatment regime $sign[\delta(x)]$

- Obviates the need to fit-in prognostic (main) effects
- Estimates optimal treatment regime by fitting a weighted classifier for treatment as a “response” with **outcome-based** weights
$$w(y, \mathbf{x}) = \frac{y}{Pr(T=t|X=\mathbf{x})}$$
- Patients who did well on their actual treatment would high costs of misclassification and likely to have their optimal treatment estimated to be the same treatment they received
- Weights incorporate the probabilities of treatment which are known in RCT and can be obtained by modeling propensity of treatment assignment in observational (non-randomized) studies




■ Some recent methods

- Outcome weighted learning (OWL) introduced by Zhao et al. (2012)
- Robust kernel method by Huang and Fong (2014)
- ROWSi method by Xu et al (2015)
- Tree- and list-based ITR (Zhang et al, 2012; Laber et al, 2015; Zhang et al, 2016; Fu et al, 2016)

LOCAL TREATMENT EFFECT MODELING (SUBGROUP SEARCH)

- Identifying subgroups S with enhanced treatment effect $\delta(x) > \delta^*$ for $x \in S$
 - Instead of estimating the response function $\delta(x)$ in the entire covariate space first, and then carving out the interesting part where $\delta(x) > \delta^*$, these methods would directly search for such interesting regions
- Some recent methods:
 - Subgroup search methods of Kehl and Ulm (2006), Chen et al. (2015) (inspired by Bump Hunting a.k.a. PRIM by Fisher and Friedman, 1999)
 - SIDES (by Lipkovich et al, 2011) and SIDEScreen (Lipkovich and Dmitrienko, 2014)
 - TSDT by Battioui et al (2018)
 - Sequential-BATting, Huang et al (2017)
 - Bayesian model averaging (Berger et al, 2014)



SOFTWARE FOR SUBGROUP IDENTIFICATION

Software for subgroup identification

SIDES method

R package *SIDES* implementing the regular SIDES method (Subgroup Identification Based on Differential Effect Search) based on [Lipkovich et al. \(2011\)](#) [last update: October 04, 2016]. The package is maintained by Marie-Karelle Riviere (eldamjrh@gmail.com).

Download the *SIDESxl* package (an Excel add-in) which implements the regular SIDES and SIDEScreen methods [last update: March 25, 2016]. The package is maintained by Ilya Lipkovich (ilya.lipkovich@gmail.com).

Download the R functions, C++ functions (*sides64.dll*), and examples for the regular SIDES (Lipkovich et al, 2011), SIDEScreen (Lipkovich and Dmitrienko, 2014), and Stochastic SIDEScreen (Lipkovich et al, 2017) methods [last update: October 01, 2018]. The functions and examples are provided by Ilya Lipkovich (ilya.lipkovich@gmail.com), Alex Dmitrienko and Bohdana Ratitch.

Interaction Trees method

Download the R functions and examples for the Interaction Trees method [last update: Dec 30, 2014]. The functions and examples are provided by Xiaogang Su ([Xiaogang Su's site](#)). Download the R code for the Interaction Trees method [last update: Dec 30, 2014].

Virtual Twins method

Download the R code for the *Virtual Twins method* [last update: Dec 30, 2014]. The code is provided by Jared Foster (jaredcf@umich.edu). R package *aVirtualTwins* that implements an adaptation of the Virtual Twins method by [Foster et al. \(2011\)](#)

GUIDE package

GUIDE package for classification and regression trees now includes methods for subgroup identification. The *GUIDE* package is maintained by Wei-Yin Loh ([Wei-Yin Loh's site](#)). For more information on the subgroup identification features, see Section 5.10 of the *GUIDE User Manual* [last update: September 25, 2018] and [paper](#) by Wei-Yin Loh, Xu He and Michael Man.

QUINT method

Quint package for *QU*alitative *I*nteraction *T*rees. The package is maintained by Elise Dusseldorp ([Elise Dusseldorp's site](#)) and colleagues. Reference: [Dusseldorp and Mechelen \(2014\)](#).

FindIt method

FindIt package for finding heterogeneous treatment effects [last update: February 27, 2015]. Reference: [Imai and Ratkovic \(2013\)](#).

Blasso method

Download the R functions for the Bayesian two-stage Lasso strategy for biomarker selection for time-to-event endpoints [last update: December 16, 2014]. The code is provided by Xuemin Gu (xuemin.gu@bms.com). Reference: [Gu, Yin and Lee \(2013\)](#).

ROWSi method

Download the R code for the ROWSi method (Regularized Outcome Weighted Subgroup identification). Reference: [Yu et al. \(2015\)](#).

Model-based Recursive Partitioning

R *partykit* package: A Toolkit for Recursive **P**artyitioning, which can perform subgroup analyses using the functions `lmtree()`, `glmtree()` (or more generally, `mob()`) and `ctree()`.

Recently a new package *model4you* has been created that specializes on stratified and personalized treatment effect estimation. The package is maintained by Heidi Seibold (heidi@seibold.co).

Other sources:

R package *personalized* (maintained by Jared Huling) for subgroup identification and estimation of heterogeneous treatment effects. It is a general framework that encompasses a wide range of methods including ROWSi, outcome weighted learning, and many others. See [documentation](#) and [article](#) explaining the underlying methodology.

R package *SubgrID* implements several algorithms for developing threshold-based multivariate (prognostic/predictive) biomarker signatures via bootstrapping and aggregating of thresholds from trees (BATTing), Monte-Carlo variations of the Adaptive Indexing Method (AIM) by [Huang X. et al. \(2017\)](#) and adaptation of Patient Rule Induction Method (PRIM) for subgroup identification by [Chen G. et al. \(2015\)](#).

[Fu, Zhou and Faries \(2016\)](#) developed a search approach that provides simple and interpretable rules defining subgroup of patients with maximizes average patients' benefit for different treatments within a general framework of outcome weighted learning (OWL). [Here](#) you can find the C++ implementation.

R package *DynTxRegime* implements methods to estimate dynamic treatment regimes using Interactive Q-Learning, Q-Learning, weighted learning, and value-search methods based on Augmented Inverse Probability Weighted Estimators and Inverse Probability Weighted Estimators.

R package *listdr* constructs list-based rules (lists of if-then clauses) to estimate the optimal dynamic treatment regime based on the approach by [Zhang et al. \(2016\)](#).

The *subtee* R package implements method for bootstrap-corrected estimation after subgroup selection described in [Rosenkranz \(2016\)](#) and a model averaging approach from [Bornkamp et al. \(2016\)](#).

TSDT: Treatment-Specific Subgroup Detection Tool by Chakib Battioui, Brian Denton, and Lei Shen (2018).

<http://biopharmnet.com/subgroup-analysis-software/>

WHAT FEATURES OF A SA METHOD WE SHOULD LOOK FOR?

- What is the number of candidate predictors that can be processed in efficient manner ($p=1, 20, 100, 1000$)?
- What is the “model space” induced by the procedure and how model complexity is controlled to prevent overfitting?
- What outputs does the method produce?
 - Signatures of promising subgroups
 - Personalized treatment contrast
 - Optimal treatment assignment
 - Predictive biomarkers ordered by predictive strength.
- How the false discovery is controlled, if at all (type I error control, FDR)
- Does the method provide “honest” estimates (point estimates, SE, CI) of treatment effect in identified subgroups corrected for over-optimism?
 - E.g. using cross-validation, bootstrap, Bayesian model averaging

SUMMARY OF SUBGROUP IDENTIFICATION METHODS

| Method | Modeling type (1) | Dimensionality (2) | Biomarker selection (3) | Control of false positive rate (4) | Complexity control (5) | Selection control (6) | Honest estimate of treatment effect (7) | Software implementation (8) |
|--|-------------------|--------------------|-------------------------|------------------------------------|------------------------|-----------------------|---|-----------------------------|
| Global outcome modeling | | | | | | | | |
| STIMA (Dusseldorp et al. 2010) | Freq/NP | Medium | S | No | Yes | No | No | R [stima] |
| Virtual Twins (Foster et al., 2011) | Freq/NP | High | P,S | No | Yes | No | Yes | R [aVirtualTwins] |
| FindIt (Imai and Ratkovic, 2013) | Freq/P | High | | No | Yes | No | No | R [FindIt] |
| Bootstrap-corrected estimation after model selection (Rosenkranz, 2016) | Freq/P | Low | S | Yes | | Yes | No | R [subtee] |
| Bayesian linear models (Dixon and Simon, 1991; Hodges et al., 2007) | Bayes/P | Low | P | No | Yes | No | Yes | R [DSBayes] |
| Bayesian trees (Henderson et al., 2017; Zhao et al., 2018) | Bayes/SP | High | P | No | Yes | No | Yes | R [AFTrees] |
| Global treatment effect modeling | | | | | | | | |
| STEPP (Bonetti and Gelber, 2000) | Freq/NP | Low | P | Yes | | | No | R [stepp] |
| Multivariable fractional polynomials (Royston and Sauerbrei, 2004, 2013) | Freq/NP | Low | P | Yes | | | No | R [mfp] |
| Interaction Trees (Su et al., 2009) | Freq/NP | Medium | S | No | Yes | No | No | B |
| Modified covariate method (Tian et al., 2012) | Freq/P | High | P | No | Yes | No | No | |
| QUINT (Dusseldorp and Mechelen, 2014) | Freq/NP | Medium | S | No | Yes | No | No | R [quint] |
| Gi as part of GUIDE (Loh et al., 2015, 2016) | Freq/NP | Medium | B,S | No | Yes | Yes | Yes | B |
| Model-based trees and forests (Seibold et al., 2016, 2018) | Freq/NP | High | B,P,S | Yes | Yes | Yes | Yes | R [model4you] |
| Causal random forests (Wager and Athey, 2018) | Freq/NP | High | B,P | No | Yes | No | Yes | R [grf] |
| Optimal treatment regimes | | | | | | | | |
| Biomarker selector (Gunter et al., 2011) | Freq/P | High | B | Yes | Yes | No | No | |
| Qian and Murphy (2011) | Freq/P | High | P,T | No | Yes | No | No | |
| AIPWE estimator by Zhang et al. (2012) | Freq/SP | Medium | T | No | Yes | No | No | R [DynTxRegime] |
| Zhao et al. (2012), Xu et al. (2015) | Freq/P | High | P,T | No | Yes | No | No | R [personalized] |
| Tree- and list-based ITR (Laber et al., 2015; Zhang et al., 2016; Fu et al., 2016) | Freq/NP | Medium | P,T | No | Yes | No | No | B,R [listdtr] |
| Local modeling | | | | | | | | |
| SIDES (Lipkovich et al., 2011); SIDEScreen (Lipkovich and Dmitrienko, 2014) | Freq/NP | Medium | B,S | Yes | Yes | Yes | Yes | B,R [SIDES] |
| Adaptation of PRIM (Chen et al., 2015) | Freq/NP | Medium | S | No | Yes | No | No | R [SubgrpID] |
| Sequential-Batting (Huang et al., 2017) | Freq/NP | Medium | S | Yes | Yes | Yes | Yes | R [SubgrpID] |
| TSDT (Battoui, Denton and Shen, 2018) | Freq/NP | Medium | B,S | Yes | Yes | No | Yes | R [TSDT] |
| Bayesian Model Averaging (Berger et al. 2014; Bornkamp et al., 2016) | Bayes/NP | Low | S | Yes | Yes | No | Yes | P, R [subtee] |

Updated from Lipkovich, Dmitrienko, D'Agostino. Tutorial in biostatistics... , SIM 2017

SUMMARY

- We emphasize **principled** or **disciplined** use of subgroup identification as opposed to haphazard data-dredging and treat subgroup identification as a special case of **model selection**, contrasting data-driven with guideline-driven approach
- Unlike standard predictive modeling methods that aim at identifying subgroups with heterogeneous outcome, using methods for tailoring/personalized medicine requires modeling individual treatment differences targeting subgroups with **heterogeneous treatment effect**
- Methods for subgroup identification and analysis borrow from diverse literature in **machine learning, multiple testing and causal inference**
- A feature of subgroup identification (and data mining in general) in drug development is **the need to control the Type I error** (or false discovery) rates which is a relatively new trend in the area of machine learning
- Once subgroups have been identified, analyst is facing the challenge of **obtaining “honest”** estimates for associated effects that should be expected in the **future** data

REFERENCES

- Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives. *Health Technology Assessment* 2001, 5(33)
- Chen, G., Zhong, H, Belousov, A. Viswanath, D. PRIM Approach to Predictive-signature Development for Patient Stratification. *Statistics in medicine* 2015. 34:317-342.
- Foster JC, Taylor JMC, Ruberg SJ, Subgroup identification from randomized clinical trial data, *Statistics in medicine* 2011, 30:2867–2880.
- Jones HE, Ohlssen DI, Neuenschwander B, Racine A and Branson M. Bayesian models for subgroup analysis in clinical trials. *Clinical Trials* 2011; 8:129–143.
- Kehl V and Ulm K. Responder identification in clinical trials with censored data. *Computational Statistics & Data Analysis* 2006, 50:1338-1355.
- Lipkovich I, Dmitrienko A, Denne J, Enas G. Subgroup identification based on differential effect search (SIDES): A recursive partitioning method for establishing response to treatment in patient subpopulations. *Statistics in Medicine* 2011, 30:2601-2621.
- Lipkovich I, Dmitrienko A. Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES. *Journal of Biopharmaceutical Statistics* 2014, 24:130-153.
- Lipkovich I, Dmitrienko A, D'Agostino BR. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials. *Statistics in Med* 2017. 36:136-196.
- Loh, W-Y., He, X., Man, M. A regression tree approach to identifying subgroups with differential treatment effects. *Statistics in medicine* 2015. 34:1818-1833.
- Rothwell PM. Subgroup analysis in randomized controlled trials: importance, indications, and interpretation. *Lancet* 2005; 365:176–86
- Seibold H, Zeileis A, Hothorn T. Model-based recursive partitioning for subgroup analyses. *International journal of Biostatistics* 2016; 12:45-63.
- Su X, Tsai CL, Wang H, Nickerson DM, Li B. Subgroup analysis via recursive partitioning. *Journal of Machine Learning Research* 2009; 10:141-158.
- Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses, *BMJ* 2010; 340:c117doi: 10.1136/bmj.c117
- Tian L, Alizaden AA, Gentles AJ, Tibshirani R. A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates *Journal of the American Statistical Association* 2014; **109**:1517–1532.
- Xu Y, Yu M, Zhao YQ, Li Q, Wang S, Shao J. Regularized outcome weighted subgroup identification for differential treatment effects. *Biometrics* 2015. 71:645-653.
- Zhao Y, Zheng D, Rush AJ, Kosorok MR. Estimating individualized treatment rules using outcome weighted learning. *Journal of the American Statistical Association* 2012, 107:1106-1118.



THANK YOU!

Ilya.Lipkovich@Lilly.com